Propella Therapeutics, Inc. announced nonclinical data for its lead product candidate, PRL-02, will be presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium. PRL-02 is being evaluated in an ongoing Phase 1 study for patients with advanced prostate cancer.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-12-07 09:43:112022-02-15 09:20:10Press Release: Propella Therapeutics Invited to Present at 2022 ASCO Genitourinary (GU) Cancers Symposium and to Participate in the LifeSci Partners 11th Annual Corporate Access Event
Propella Therapeutics, Inc., a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-06-29 15:42:032022-01-04 09:10:09Press Release: Propella Announces First Patient Dosed in Phase 1/2a Trial of PRL-02 for Treatment of Metastatic Prostate Cancer; Next-Generation Androgen Biosynthesis Inhibitor with Long Duration of Activity and Superior Therapeutic Index
Propella Therapeutics, Inc. presented “A Phase 1/2a, Open-label, Multicenter Study of Intramuscular Abiraterone Decanoate (PRL-02) Depot in Patients with Advanced Prostate Cancer (NCT04729114)” at the American Society of Clinical Oncology Annual Meeting in San Francisco, CA on June 4, 2021.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-06-07 20:44:282022-09-12 12:32:10Presentation at the American Society of Clinical Oncology Annual Meeting (June 4, 2021; San Francisco, CA): A Phase 1/2a, open-label, multicenter study of intramuscular abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114)
Propella Therapeutics, Inc., a biopharmaceutical company focused on developing innovative, best-in-class oncology drugs, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PRL-02 (abiraterone decanoate), a potentially best-in-class therapy for metastatic prostate cancer. Propella also announced the appointment of Brendan Griffin to its leadership team as Chief Financial Officer.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-05-19 19:12:482022-01-04 09:10:35Press Release: Propella Therapeutics Receives FDA Clearance to Begin Phase 1 Clinical Study of Novel Prostate Cancer Treatment; Appoints Brendan Griffin, MBA as Chief Financial Officer
Presentation at the 11th Annual LifeSci Partners Corporate Access Event (January 5-7, 2022): Propella Therapeutics Corporate Presentation
/in presentations /by georgePropella Therapeutics, Inc. participated in the 11th Annual LifeSci Partners Corporate Access Event from January 5-7, 2022.
Press Release: Propella Therapeutics Invited to Present at 2022 ASCO Genitourinary (GU) Cancers Symposium and to Participate in the LifeSci Partners 11th Annual Corporate Access Event
/in press releases /by georgePropella Therapeutics, Inc. announced nonclinical data for its lead product candidate, PRL-02, will be presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium. PRL-02 is being evaluated in an ongoing Phase 1 study for patients with advanced prostate cancer.
Presentation at the MedInvest Oncology Conference (December 7-10, 2021): Propella Therapeutics Corporate Presentation
/in presentations /by georgePropella Therapeutics, Inc. presented at the MedInvest Oncology Conference on December 7, 2021.
Press Release: Propella Announces First Patient Dosed in Phase 1/2a Trial of PRL-02 for Treatment of Metastatic Prostate Cancer; Next-Generation Androgen Biosynthesis Inhibitor with Long Duration of Activity and Superior Therapeutic Index
/in press releases /by georgePropella Therapeutics, Inc., a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer.
Presentation at the American Society of Clinical Oncology Annual Meeting (June 4, 2021; San Francisco, CA): A Phase 1/2a, open-label, multicenter study of intramuscular abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114)
/in presentations /by georgePropella Therapeutics, Inc. presented “A Phase 1/2a, Open-label, Multicenter Study of Intramuscular Abiraterone Decanoate (PRL-02) Depot in Patients with Advanced Prostate Cancer (NCT04729114)” at the American Society of Clinical Oncology Annual Meeting in San Francisco, CA on June 4, 2021.
Press Release: Propella Therapeutics Receives FDA Clearance to Begin Phase 1 Clinical Study of Novel Prostate Cancer Treatment; Appoints Brendan Griffin, MBA as Chief Financial Officer
/in press releases /by georgePropella Therapeutics, Inc., a biopharmaceutical company focused on developing innovative, best-in-class oncology drugs, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PRL-02 (abiraterone decanoate), a potentially best-in-class therapy for metastatic prostate cancer. Propella also announced the appointment of Brendan Griffin to its leadership team as Chief Financial Officer.